Published in Front Cell Neurosci on August 20, 2014
Editorial Research Topic "Chemokines and chemokine receptors in brain homeostasis". Front Cell Neurosci (2015) 0.77
Palmitoylethanolamide in Fibromyalgia: Results from Prospective and Retrospective Observational Studies. Pain Ther (2015) 0.76
Synthesis, solubility, plasma stability, and pharmacological evaluation of novel sulfonylhydrazones designed as anti-diabetic agents. Drug Des Devel Ther (2016) 0.75
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (1998) 13.58
Origin and physiological roles of inflammation. Nature (2008) 11.68
The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 10.99
PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature (1998) 10.09
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature (2005) 7.07
Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A (1987) 6.90
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature (2005) 6.83
Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet (1999) 6.09
Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci (2009) 5.00
Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science (2003) 3.97
Prevalence of chronic pain with neuropathic characteristics in the general population. Pain (2007) 3.72
The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain (2006) 3.67
Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nat Rev Immunol (2010) 3.60
Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A (2003) 3.17
Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience (2004) 2.84
Chemokines and glycoprotein120 produce pain hypersensitivity by directly exciting primary nociceptive neurons. J Neurosci (2001) 2.79
Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc Natl Acad Sci U S A (2002) 2.72
Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res (2000) 2.61
Immune and inflammatory mechanisms in neuropathic pain. Brain Res Rev (2006) 2.59
Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res (2000) 2.52
Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. Proc Natl Acad Sci U S A (2005) 2.50
PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci U S A (2003) 2.40
MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia. J Neurophysiol (2006) 2.38
Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha. J Pharmacol Exp Ther (2006) 2.30
Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci (2007) 2.28
Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther (2010) 2.27
Spatial and temporal relationship between monocyte chemoattractant protein-1 expression and spinal glial activation following peripheral nerve injury. J Neurochem (2006) 2.14
Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci (2004) 2.11
Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron (2012) 2.11
Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons. J Neurochem (2007) 1.93
Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci (2004) 1.89
Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun (2006) 1.88
A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1. Proc Natl Acad Sci U S A (2005) 1.82
Molecular evolution of CXC chemokines: extant CXC chemokines originate from the CNS. Trends Immunol (2003) 1.77
Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol (1999) 1.75
Chemokines: integrators of pain and inflammation. Nat Rev Drug Discov (2005) 1.68
Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J Cereb Blood Flow Metab (2006) 1.67
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem (2004) 1.61
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem (2007) 1.61
Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. Inflammopharmacology (2013) 1.61
Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J Pain (2005) 1.60
Properties of afferent nerve impulses originating from a neuroma. Nature (1974) 1.59
Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab (2006) 1.57
Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther (2006) 1.52
Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice. Arthritis Res Ther (2013) 1.49
The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today (2006) 1.49
Defining the origins and evolution of the chemokine/chemokine receptor system. J Immunol (2006) 1.48
CCL2 and CXCL1 trigger calcitonin gene-related peptide release by exciting primary nociceptive neurons. J Neurosci Res (2005) 1.48
The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology (2008) 1.46
The role of the immune system in the generation of neuropathic pain. Lancet Neurol (2012) 1.41
PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res (2008) 1.41
Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem (2008) 1.37
Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells. Eur J Immunol (2001) 1.36
Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. J Neurosci (2002) 1.36
Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce? Neurotherapeutics (2007) 1.34
Functional downregulation of P2X3 receptor subunit in rat sensory neurons reveals a significant role in chronic neuropathic and inflammatory pain. J Neurosci (2002) 1.33
Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia. J Neurosci Res (2005) 1.32
Multiple expression control mechanisms of peroxisome proliferator-activated receptors and their target genes. J Steroid Biochem Mol Biol (2005) 1.32
Peroxisome proliferator-activated receptor-gamma agonists inhibit the activation of microglia and astrocytes: implications for multiple sclerosis. J Neuroimmunol (2005) 1.30
Effects of interleukin-10 (IL-10) on pain behavior and gene expression following excitotoxic spinal cord injury in the rat. Exp Neurol (2001) 1.29
The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci (2009) 1.26
Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol (2005) 1.25
Deletion of PPAR gamma in alveolar macrophages is associated with a Th-1 pulmonary inflammatory response. J Immunol (2009) 1.23
PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol (2002) 1.22
Increased chemokine signaling in a model of HIV1-associated peripheral neuropathy. Mol Pain (2009) 1.22
Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice. J Pharmacol Exp Ther (2007) 1.18
CCL2 released from neuronal synaptic vesicles in the spinal cord is a major mediator of local inflammation and pain after peripheral nerve injury. J Neurosci (2011) 1.17
High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol (2010) 1.16
Neuronal MCP-1 expression in response to remote nerve injury. J Cereb Blood Flow Metab (2001) 1.16
PPARgamma in monocytes: less pain, any gain? Cell (1998) 1.15
Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-kappaB nuclear signalling in dorsal root ganglia. Eur J Pharmacol (2009) 1.14
Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats. J Pain (2008) 1.14
Force-dependent development of neuropathic central pain and time-related CCL2/CCR2 expression after graded spinal cord contusion injuries of the rat. J Neurotrauma (2008) 1.14
Neuropathic pain after traumatic spinal cord injury--relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord (2004) 1.14
Early cytokine expression in mouse sciatic nerve after chronic constriction nerve injury depends on calpain. Brain Behav Immun (2007) 1.13
Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. J Nutr Biochem (2007) 1.13
Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol (2000) 1.12
Effects of palmitoylethanolamide on signaling pathways implicated in the development of spinal cord injury. J Pharmacol Exp Ther (2008) 1.12
TNF-alpha expression in painful and nonpainful neuropathies. Neurology (2001) 1.11
Chronic spontaneous activity generated in the somata of primary nociceptors is associated with pain-related behavior after spinal cord injury. J Neurosci (2010) 1.10
Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem (2010) 1.10
Peroxisome proliferator-activated receptor α mediates acute effects of palmitoylethanolamide on sensory neurons. J Neurosci (2012) 1.10
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model. Lab Invest (2003) 1.09
Unmet needs in the management of neuropathic pain. J Pain Symptom Manage (2003) 1.08
Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration. Eur J Pharmacol (2004) 1.07
Pathology of experimental compression neuropathy producing hyperesthesia. J Neuropathol Exp Neurol (1993) 1.07
Chemokine receptor antagonists: Part 1. Expert Opin Ther Pat (2009) 1.06
CXCR4 signaling mediates morphine-induced tactile hyperalgesia. Brain Behav Immun (2010) 1.05
Spatiotemporal CCR1, CCL3(MIP-1α), CXCR4, CXCL12(SDF-1α) expression patterns in a rat spinal cord injury model of posttraumatic neuropathic pain. J Neurosurg Spine (2011) 1.05
Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem (2010) 1.03
S. aureus-dependent microglial activation is selectively attenuated by the cyclopentenone prostaglandin 15-deoxy-Delta12,14- prostaglandin J2 (15d-PGJ2). J Neurochem (2004) 1.03
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol (2010) 1.02
Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol Disord Drug Targets (2011) 1.01